McLean Hospital

Patient-Reported Changes in Alcohol Use Following Glucagon-Like Peptide-1 Receptor Agonist Initiation

This survey study with a nationally representative sample evaluates whether individuals who initiate glucagon-like peptide-1 receptor agonists (GLP-1 RAs) report reducing alcohol consumption after starting the drug.

Tobacco use moderates associations between cannabis use, psychiatric symptoms, and cognitive performance in psychosis spectrum disorders

Tobacco and cannabis use are highly prevalent among individuals with psychotic disorders. Tobacco use has been consistently linked to poorer clinical and cognitive outcomes, whereas findings regarding cannabis use remain mixed. The present study was a secondary analysis of cross-...

Exclusion of Participants for Substance Use in Clinical Trials

Patterns of inclusion and exclusion of individuals who use illicit substances from clinical trials have not been well-studied. Given the widespread and increasing prevalence of drug use in the United States, this has significant implications for the generalizability of scientific...

Setting of Alcohol Use Disorder Diagnosis Among Women Enrolled in Medicare

OBJECTIVE: The authors assessed the setting of an initial diagnosis of alcohol use disorder among Medicare-enrolled women. METHODS: Using 2016-2022 Medicare fee-for-service claims, the authors identified the first alcohol use disorder diagnosis for women ages 18-64 years (N=116,2...

Assessing Individual Differences in Adult Theory of Mind Through Mental State Language: Human and Artificial Intelligence Approaches

Theory of mind is central to human social behavior, yet empirical studies rely largely on biased measures with limited ecological validity. We propose and evaluate the use of mental state language as a spontaneous indicator of theory of mind expressed in social interaction. Among...

Toward actionable biomarkers in psychiatry: a collaborative roadmap for precision clinical trials. An ACNP position paper

Abstract Psychiatric drug development remains constrained by diagnostic heterogeneity, insufficient and inconsistent drug response, high placebo response rates, and the absence of validated biomarkers that can reliably guide patient stratification, trial design, and regulatory de...

The YTHDF proteins modulate Alzheimer’s disease-associated brain gene signatures

Abstract Gene signatures of Alzheimer’s disease (AD) brains reflect the output of a complex interplay of genetic, epigenetic, epi-transcriptomic, and post-transcriptional regulations. To nominate candidate factors modulating these signatures, we developed a machine learning model...

A non-neuronal fMRI signal: both a confound and an opportunity for insight

Abstract Functional magnetic resonance imaging (fMRI) is widely used to investigate brain function. However, interpretation of the blood oxygen level-dependent (BOLD) signal is complicated by the fact that it reflects both neuronal activity and vascular physiology. This problem i...